Home›Stock Screener›Gennex Laboratories

Gennex Laboratories Share Price Today | Stock Price & Gennex Laboratories Share Screener

GENNEX Pharmaceuticals & Biotechnology
Live Share Price BSE
₹8.87
▼ -0.10 (-1.11%)
2026-11-20 00:00:00

As of November 20, 2026, the live Gennex Laboratories share price (BSE: GENNEX) is ₹8.87, down 1.11% from the previous close, with shares trading between ₹8.66 and ₹9.09 in today's trading session, and a 52-week range of ₹7.13–₹14.77. Track GENNEX market value to gauge the company's total market size. Use the Gennex Laboratories stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Gennex Laboratories opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.

Key Statistics and Valuation Ratios

Over the trailing twelve months the company reported revenue of ₹44 and net income of ₹5, with EBITDA of ₹7, an operating margin of 13.0% and a profit margin of 11.4%.

Gennex Laboratories Market Cap ₹218.63 Cr.
GENNEX P/E Ratio (TTM) 11.10
Gennex Laboratories P/B Ratio 1.03
EPS (TTM) ₹0.87
Dividend Yield -
Debt to Equity 0.11
GENNEX 52 Week High ₹14.77
Gennex Laboratories 52 Week Low ₹7.13
Operating Margin 13.00%
Profit Margin 11.36%
GENNEX Revenue (TTM) ₹44.00
EBITDA ₹7.00
Net Income ₹5.00
Total Assets ₹349.00
Total Equity ₹233.00

Gennex Laboratories Share Price Chart

Track the current stock price of Gennex Laboratories with an interactive chart. Analyse GENNEX share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Gennex Laboratories stock quote in one place.

The quote of ₹8.87 sits between the 52-week low of ₹7.13 and the 52-week high of ₹14.77, and the latest session moved -1.11% from the previous close.

Gennex Laboratories Company Profile - Fundamental Screener

Screen Gennex Laboratories company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for GENNEX shares across the equity market and its stock price history, plus the wider market trend.

The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, and it trades under ISIN INE509C01026.

Company Details

Classification

Sector Healthcare
Industry Pharmaceuticals & Biotechnology
Sub-Sector Pharmaceuticals & Biotechnology
Segment E

Identifiers and Leadership

ISIN INE509C01026

Gennex Laboratories Balance Sheet Screener

Screen GENNEX balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.

For 2026, total assets were ₹349, up from ₹256 in 2025.

Latest statistics put total assets at ₹349 and shareholder funds at ₹233, with a leverage ratio of 0.11.

Item 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017

Assets

Total Assets 349 256 230 132 68 59 57 52 51 49
Current Assets 0 0 0 0 0 0 0 0 0 0
Fixed Assets 61 60 56 74 14 14 15 16 16 16

Liabilities

Total Liabilities 0 0 0 0 0 0 0 0 0 0
Current Liabilities 43 17 13 16 0 0 0 1 1 1
Non-Current Liabilities 0 0 0 0 0 0 0 0 0 0

Shareholders' Equity

Total Equity 233 195 177 87 44 40 36 34 32 31
Share Capital 24 23 23 18 13 13 13 13 13 13
Reserves & Surplus 198 158 142 62 31 27 23 21 19 18

Gennex Laboratories Income Statement Screener - Profit & Revenue Analysis

Screen Gennex Laboratories income statement and profit fundamentals. Analyze GENNEX quarterly results. Gennex Laboratories reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.

For 2026-Sept, revenue was ₹44 and net profit was ₹5, equal to earnings per unit of ₹0.17, at an operating margin of 13%.

In that period expenses were ₹37, interest cost ₹1 and tax ₹0. The next period listed, 2026-Jun, shows revenue of ₹42 and net profit of ₹5.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jun 2025-Mar 2024-Dec 2024-Sept 2024-Jun 2024-Mar 2023-Dec 2023-Sept 2023-Jun 2023-Mar

Revenue and Expenses

Revenue 44 42 62 40 37 37 44 38 32 31 34 19 18 17 19
Expenses 37 36 55 35 32 29 39 33 26 24 29 17 12 11 17

Operating Costs and Margins

EBITDA 7 6 7 6 6 7 6 5 6 7 4 3 5 5 1
Operating Profit % 13.00% 11.00% 9.00% 14.00% 15.00% 15.00% 5.00% 13.00% 18.00% 15.00% 13.00% 13.00% 29.00% 31.00% 7.00%
Depreciation 1 1 1 1 1 1 1 1 1 0 0 0 1 1 0
Interest 1 1 1 1 1 1 1 1 0 1 1 1 1 1 1

Profit and Earnings

Profit Before Tax 5 5 5 7 6 6 4 6 6 6 5 4 4 4 3
Tax 0 0 0 1 1 1 1 1 1 1 1 1 1 1 1
Net Profit 5 5 5 6 6 5 3 5 5 5 5 3 3 3 2
EPS 0.17 0.19 0.16 0.22 0.21 0.22 0.14 0.22 0.21 0.19 0.16 0.16 0.16 0.16 0.19

Gennex Laboratories Cash Flow Screener - Liquidity Fundamentals

Screen GENNEX cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.

In 2026-March, operating activities used ₹64, and net cash flow was an outflow of ₹3.

Over the same period, investing activities used ₹5 and financing activities provided ₹65.

Item 2026-March 2025-March 2024-March 2023-March 2022-March 2021-March 2020-March 2019-March 2018-March 2017-March

Cash from Operations and Investing

Operating Activities -64 -10 -47 24 12 -1 -2 2 3 0
Investing Activities -5 3 19 -38 -3 0 0 -1 -1 -1

Financing and Net Cash

Financing Activities 65 2 74 21 -2 2 0 1 -2 1
Net Cash Flow -3 -5 46 6 8 0 -2 2 0 0

Gennex Laboratories Shareholding Pattern Screener

See Gennex Laboratories shareholding pattern with promoter, FII, and DII holdings. Check Gennex Laboratories promoter holding and ownership changes for GENNEX on TickJournal, and see how institutional stock price moves affect the market.

In 2026-Sept, promoters held 23.63%, foreign institutions 0.00%, domestic institutions 0.00% and the public 56.30%, spread across 81,481 shareholders.

The shareholder count was 81,481 in 2026-Sept, compared with 82,886 in 2026-Jun.

Item 2026-Sept 2026-Jun 2026-Mar 2025-Dec 2025-Sept 2025-Jul 2025-Jun 2025-Mar

Promoter Holding

Promoter Holding 23.63% 23.63% 23.63% 23.62% 23.62% 23.62% 19.83% 18.42%

Institutional Investors

FII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
DII Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Government, Public and Others

Govt Holding 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Public Holding 56.30% 56.49% 55.79% 56.47% 59.34% 58.97% 61.90% 62.19%
Other Holding 20.07% 19.88% 20.58% 19.91% 17.04% 17.41% 18.28% 19.39%
Shareholder Count 81,481 82,886 84,133 86,306 90,320 91,183 91,183 92,326

Dividend Yield Screener - Share Price & Share Analysis

Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Gennex Laboratories. Gennex Laboratories dividend yield can be compared with peers and other stocks in the market.

No dividends declared by Gennex Laboratories.

Gennex Laboratories Stock Index Membership - Nifty & Sensex

See which indices include Gennex Laboratories stock. Check GENNEX index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.

Complete Index List

Gennex Laboratories is not part of any tracked indices.
Only major market indices are tracked in our system.

Gennex Laboratories Market Events Screener - Corporate Actions

Get Gennex Laboratories corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Gennex Laboratories stock events that may affect GENNEX share price, along with derivatives, futures and options activity and sector gainers.

15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 14, 2026, with a record date of November 14, 2026.

It is followed by Annual General Meeting dated September 30, 2026 and Quarterly Result Announcement dated August 14, 2026.

Announcement Date Record Date Event Type Information Price Impact
2026-11-14 2026-11-14 Quarterly Result Announcement NA 15.23%
2026-09-30 2026-09-30 Annual General Meeting NA -14.58%
2026-08-14 2026-08-14 Quarterly Result Announcement NA 6.23%
2026-05-30 2026-05-30 Quarterly Result Announcement NA 28.92%
2026-05-12 2026-05-12 Extraordinary General Meeting NA -2.64%
2026-02-14 2026-02-14 Quarterly Result Announcement NA -1.68%
2025-11-14 2025-11-14 Quarterly Result Announcement NA 1.36%
2025-09-30 2025-09-30 Annual General Meeting NA -0.44%
2025-08-14 2025-08-14 Quarterly Result Announcement NA -4.23%
2025-05-30 2025-05-30 Quarterly Result Announcement NA 5.19%
2025-02-14 2025-02-14 Quarterly Result Announcement NA -6.70%
2024-11-14 2024-11-14 Quarterly Result Announcement NA -5.88%
2024-09-30 2024-09-30 Annual General Meeting NA 27.26%
2023-12-30 2023-12-30 Extraordinary General Meeting NA 4.41%
2022-07-21 2022-07-22 Rights 1:2 2.40%

Gennex Laboratories Competitors Screener - Peer Stocks Comparison

Screen GENNEX competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.

The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.

Company Market Cap P/E Ratio Revenue YoY Growth Net Profit RSI
Sun Pharmaceutical 448,076 41.10 61,674 12.69% 11,565 59.98
Divis Laboratories 294,139 90.70 11,067 13.95% 2,568 67.88
Torrent Pharmaceuticals 178,438 84.50 13,886 20.34% 2,138 49.31
Laurus Labs 119,949 98.10 6,868 22.01% 890 49.19
Zydus Life Science 118,902 27.60 27,658 17.64% 5,026 52.87
Dr Reddys Laboratories 115,011 41.70 35,059 3.90% 4,158 69.34
Cipla 112,656 39.40 29,045 2.24% 3,870 55.82
Mankind Pharma 108,490 48.40 14,636 14.85% 1,938 63.62
Aurobindo Pharma 103,223 26.40 34,145 5.56% 3,503 60.38
Lupin 90,393 17.30 29,039 26.75% 5,356 44.23

Gennex Laboratories Company Announcements - News & Reports Screener

Screen GENNEX latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.

20 recent announcements are listed, the latest dated November 21, 2026.

The next most recent announcements are dated November 21, 2026 and November 21, 2026.

Date Update Actions
2026-11-21 Intimation Regarding Dissolution Of The Rights Issue Committee Pursuant To Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 -
2026-11-21 Intimation Of Reconstitution Of Audit Committee Stakeholders Relationship Committee And Nomination And Remuneration Committee Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations 2015. -
2026-11-21 Board Meeting Outcome for Meeting Held Today I.E. 30Th September 2026 -
2026-11-20 Financial Result For The Quarter And Half Year Ended September 30 2026 -
2026-11-12 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-11-03 Board Meeting Intimation for Consideration And Approval Of The Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half-Year Ended September 30 2026. -
2026-10-13 Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 -
2026-10-01 Shareholder Meeting / Postal Ballot-Scrutinizers Report -
2026-09-30 Announcement under Regulation 30 (LODR)-Change in Management -
2026-09-30 Shareholder Meeting / Postal Ballot-Outcome of AGM -
2026-09-22 Closure of Trading Window -
2026-09-09 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-09-08 Approval Of Additional Products From Drugs Control Administration Government Of Andhra Pradesh For Our Subsidiary Company Deccan Remedies Limited -
2026-09-08 Reg. 34 (1) Annual Report. -
2026-09-04 Intimation Of Book Closure For The Purpose Of 41St AGM Of Gennex Laboratories Limited -
2026-09-04 Board Meeting Outcome for Meeting Held On September 04 2026 -
2026-08-27 Board Meeting Intimation for For Fixing Date Time And Venue Of 41St AGM Of The Company -
2026-08-17 Announcement under Regulation 30 (LODR)-Newspaper Publication -
2026-08-14 Un-Audited Financial Results For The Quarter Ended June 30 2026 -
2026-08-14 Board Meeting Outcome for Un-Audited Financial Results For The Quarter Ended June 30 2026 -

Frequently Asked Questions

How is the company valued right now?

The current quote is ₹8.87, within a 52-week range of ₹7.13 to ₹14.77. The P/E ratio is 11.10 and the P/B ratio is 1.03, with earnings per unit of ₹0.87. Market capitalisation stands at ₹218.63 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.

About This Data

Quotes are sourced from the BSE. Key statistics were last updated on November 22, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.